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Treatment outcomes for patients with Hodgkin lymphoma (HL) have improved significantly over the past three decades to the extent that 
current treatment strategies for most HL subcategories 
focus on toxicity reduction rather than further improve-
ment in disease cure.1 This has led to the development of 
risk-stratified treatment assignment with more aggres-
sive therapy limited to patients with ‘advanced’ disease. 
Unfortunately, the definition of ‘advanced’ disease var-
ies.2-6 While differences exist in the inclusion of all pa-
tients with stage III disease or only those with B symp-
toms or bulky disease in the ‘advanced’ disease category, 
all clinicians agree that stage IV is definitely high risk. 
Toxicity reduction strategies have employed multi-
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BACKGROUND AND OBJECTIVES: While treatment outcomes for patients with hodgkin lymphoma (hl) have 
improved remarkably, patients with disseminated disease still have a poorer outcome.  stage iV hl is often re-
ported with other ‘advanced stage’ categories, confusing the specific contribution of disease dissemination to the 
outcome. this single-institution report looks at characteristics and outcomes of this specific category. 
PATIENTS AND METHODS: the medical records of pediatric hl patients (<14 years) from 1975 through 2003 
were retrospectively reviewed and the data analyzed.  
RESULTS: stage iV patients (n=67) had more poor-risk characteristics than patients in stages i-iii (n=300) (b 
symptoms 86.6% vs. 19.3%, bulky disease 57.6% vs. 45.5% and mediastinal mass 77.6% vs. 29.7%; p<.001 for 
all characteristics). the liver was the most common extralymphatic site (in 51.5% of patients with stage iV dis-
ease.  stage iV patients received chemotherapy (ct) alone (n=55) or combined modality therapy (cmt) (n=12). 
fifty-four patients (80.6%) achieved complete remission, 2 (3%) partial remission, 10 (14.9%) had progressive 
disease and 1 was lost to follow up.  overall survival was 79.4% and event-free survival (efs) was 63.9% at 5 
years.  there was a non-significant benefit for cmt (os=91.7% v. 77.1%, p=.3; efs=70.7% v. 62.7%, p=.3).  ten 
of 12 relapsed and only 1 of 10 progressive disease patients were salvaged.  on multivariate analysis, failure to 
achieve complete remission with ct was associated with a poorer outcome.
CONCLUSION: stage iV disease is associated with poor risk features and confers a worse outcome than stage 
i-iii disease.  achievement of complete remission with ct is an important prognostic feature. slow responders 
may require novel and/or aggressive therapy to achieve complete remission.  
modality therapy, with the use of lower doses of both 
chemotherapy and radiation therapy. While this has 
been definitely successful in lower stage disease, the use 
of radiation therapy as consolidation in patients with 
stage IV disease remains controversial. Studies in adult 
patients seem to indicate a lack of benefit for using ra-
diation therapy in patients who have achieved a com-
plete response (CR) to chemotherapy.7 However, while 
pediatric studies continue to show a statistical benefit in 
event-free survival for involved-field radiation therapy 
(IFRT) as consolidation following CR to chemother-
apy,8 debate regarding the degree of benefit in terms of 
survival is ongoing.9 The utility of such radiotherapy 
may actually differ in different risk groups of patients. 
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Certainly, in patients with stage IV disease, due to the 
extent of disease involvement, the field of radiation that 
should be used, if all sites of initial involvement were 
irradiated, would be quite extensive. This has led many 
to attempt to treat the majority of such patients with 
only chemotherapy, while strategies to determine spe-
cific sites of involvement that should receive irradiation 
continue to evolve.6,10 
While the number of nodal sites has been shown 
to be of prognostic value, little information is available 
regarding the prognostic significance of either the num-
ber of extranodal sites involved or the specific organs 
that are involved with metastatic disease. There may 
certainly be patients with stage IV HL that are at a 
higher risk of treatment failure than others, and if these 
are identifiable they may benefit from novel or aggres-
sive therapeutic strategies. 
With these questions in mind we have studied the 
data regarding pediatric patients with stage IV HL 
treated at our institution, and have attempted to de-
termine clinical characteristics that may further define 
risk stratification in this group of high-risk patients. 
Although this is a retrospective evaluation we have 
also explored the outcome of single- versus multi-mo-
dality therapy. 
PATIENTS AND METHODS 
Medical records of HL patients diagnosed and treated 
in the pediatric hematology/oncology service at our in-
stitution from 1975 through 2003 were retrospectively 
reviewed. Data regarding the pathological diagnosis, 
staging, treatment, and outcome were collected and ana-
lyzed. The collection, analysis and reporting of this data 
was conducted under the review and approval of the 
Institutional Research Advisory Council which acts as 
the Institutional Review Board for the Department of 
Pediatric Hematology/Oncology, King Faisal Specialist 
Hospital and Research Center, Riyadh, Saudi Arabia. 
The diagnosis of HL was based on the cytomorphol-
ogy, and on the immunohistochemical and cytochemi-
cal stains. The REAL (Revised European-American 
Classification of Lymphoid Neoplasms) classification, 
and subsequently the WHO classification, were used 
for sub-categorization.11 All patients were staged ac-
cording to the Ann Arbor HL staging criteria prior to 
treatment initiation.12 Staging workup was non-surgi-
cal, and included a CT scan of the chest, and either a 
CT scan and/or an ultrasound of the abdomen. A CT 
scan was also done for all other sites with suspected 
involvement on clinical evaluation. Other radiological 
studies including plain x-rays and a gallium scan were 
conducted for several patients. In addition, a bone mar-
row aspirate and trephine biopsy were conducted on the 
majority of patients. 
Due to the extent of the disease, the treatment strat-
egy for these patients relied on systemic delivery of 
therapy using chemotherapy. The decision on use of ra-
diation therapy was left to the individual treating physi-
cian, and was therefore used in only a very few patients. 
Only 4 of 38 patients diagnosed prior to 1997 received 
radiation.  Two of these patients had documented re-
sidual disease at completion of scheduled chemothera-
py. One had bulky mediastinal disease at diagnosis and 
received 3600 cGy radiation to the mediastinum. The 
fourth patient received 3500 cGy to the mantle field 
following completion of chemotherapy; unfortunately, 
his response to chemotherapy could not be determined. 
After 1997, our strategy for radiation therapy changed, 
and based on the experience from the Hospital for 
Sick Children, Toronto,13 we started using significantly 
lower doses (1500 cGy) of radiation for consolidation 
therapy. For patients with stage IV disease radiation 
therapy was only used if patients had bulky disease 
at presentation (administered only to those sites with 
bulky disease) and to those who exhibited a slow re-
sponse to chemotherapy. Eight patients diagnosed since 
1997 received radiation therapy, and all were given the 
1500 cGy dose. 
Statistical Package for Social Sciences (SPSS) version 
13.0 was used for statistical analysis. Relative incidences 
for the clinical characteristics of patients with stage IV 
disease and those with stages I-III were compared using 
the chi square test for categorical variables and the t test 
for continuous variables. Treatment outcome was evalu-
ated using Kaplan-Meier analysis and the differences be-
tween outcomes were tested using the log-rank test.
RESULTS 
Between January 1975 and December 2003, 494 pa-
tients younger than 14 years of age were treated for HL 
at our institution. Data for 35 patients was unavailable; 
92 were diagnosed elsewhere and had initiated therapy 
there. These patients were referred to our institution 
either for radiation therapy alone, for continuation of 
first-line chemotherapy, or at the time of relapse for 
second-line therapy. These patients were not included 
in the analysis. The remaining 367 patients were diag-
nosed and received all their treatment at our institution. 
Sixty-seven (18.3%) diagnosed with stage IV disease at 
the time of their initial presentation form the basis of 
this evaluation. 
While there was no difference in the demographic 
characteristics of the patients with stage IV as com-
pared to those with stages I-III, there were significant 
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associations between stage IV disease and other known 
poor prognostic markers, such as bulky disease, medias-
tinal involvement, systemic symptoms and a lower hemo-
globin level (Table 1).  Patients with stage IV disease also 
had more sites of lymph node involvement than those 
patients with lower stage disease. The liver was the most 
frequent site of extranodal involvement, with 34 of 66 
(51.5%) patients having liver metastases. Five patients 
had nodular lesions in the kidneys. Three patients had 
pleural seeding with an effusion, while one patient had 
a soft tissue mass in the chest wall that was not contigu-
ous with any lymph node sites. Most patients had only 
one site of extranodal involvement (n=41; 62.1%). The 
liver was most often involved as the solitary metastatic 
site (n=18; 52.9% of all patients with liver involvement), 
constituting 43.9% of all patients with a single metastatic 
site. The lungs were most often associated with other sites 
of involvement; 10 (83.3%) of the 12 patients with lung 
metastases had involvement of other extranodal sites as 
well. Similarly, all five patients with kidney involvement 
also had metastatic disease in the liver or the lungs. 
Fifty-five patients were treated with chemotherapy 
alone (Table 2). Twelve patients received combined mo-
dality therapy (CMT) with chemotherapy and radiation 
therapy (Table 3). Overall, patients received a median of 
six cycles of chemotherapy (range 1-16 cycles). The 30 
patients who were treated with an ABVD-containing 
protocol (ABVD or ABVD/COPP) received a median 
of six cycles (range 4-10 cycles) of chemotherapy, while 
patients treated with other therapies (n=36; mainly 
MOPP) received a median of 6.5 cycles (range 1-16 
cycles) of therapy. Five of the patients who were treated 
with CMT received the ABVD regimen, while six were 
treated with alternating cycles of ABVD and COPP. 
One patient received MOPP chemotherapy. Nine of 
these patients achieved a compete response with che-
motherapy and then received consolidation radiation 
therapy. Eight received a 1500 cGy dose of radiation 
therapy (5 extended field and 3 involved field) while the 
ninth patient received 3600 cGy to the mediastinum. 
Two patients had residual disease at the end of chemo-
therapy and received 3000 cGy and 4140 cGy to areas 
of residual disease. The chemotherapy response status 
for one patient was unknown and he received 3500 cGy 
to a mantle field following four cycles of ABVD. 
Fifty-four (80.6%) patients achieved complete re-
sponse to first-line therapy, 2 (3%) had a partial re-
sponse, 10 (14.9%) had progressive disease (PD) and 
1 had early loss to follow-up. At a median follow-up 
of 5.6 years (mean 8.4 years; range 0.04-27.4 years) 
estimated 5-year overall survival (OS) and event-free 
survival (EFS) was 79.4% and 63.9%, respectively. The 
median follow-up for surviving patients was 7 years 
(mean 10.2 years, range 0.2-27.4 years). The outcome 
of patients with stage IV disease was significantly worse 
than that for patients with all other stages (Figure 2). 
Although statistical significance was not achieved, 
Table 1. Clinical characteristics of patients with stage IV Hodgkin 
lymphoma compared with patients in all other stages.
Stage IV
(n=67)
Stages 
I-III
(n=300)
P
Mean age (years) 8.95 8.13 .055
M:F ratio 2.53 2.95 .64
Duration of 
symptoms (mo)
   mean 9.5 8.5
.48   median 6 5.5
   range 0.2-48 0.3-72
B symptoms 58 (86.6%) 58 (19.3%) <.001
Bulky disease 
34 
(n=59; 
57.6%)
133 
(n=292; 
45.5%)
.001
Mediastinal mass 52 (77.6%) 89 (29.7%) <.001
Hemoglobin level  
(g/L)
   mean 91.6 (n=62)
116.2 
(n=288)
<.001   median 92 118
   range 36-152 60-161
Lactate 
dehydrogenase 
(U/L)
   mean 592.3 (n=42)
563.1 
(n=183)
.50   median 526 522
   range 229-1634 183-2051
Erythrocyte 
sedimentation rate 
(mm/H)
   mean 82.2 (n=28)
39.8 
(n=149)
<.001   median 91.5 24
   range 2-150 1-150
No. of lymph node 
sites involved
   mean 4.03 2.14
<.001
   median 4.0 2.0
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there was a trend towards better survival for patients 
who received radiation therapy in addition to chemo-
therapy (Figure 3). However, when we studied only 
those patients who had achieved a complete response 
to chemotherapy, the addition of radiation therapy as 
consolidation to these good responders showed only a 
marginal benefit without any statistical significance. For 
this group of patients the OS at 5 years was 100% for 
those who received radiation as compared to 91.5% for 
those who did not (P=.4; log rank test) and EFS was 
correspondingly 87.5% and 73.7% (P=.4; log rank test). 
This trend towards a better outcome with CMT could 
also have been impacted by the era of therapy. The EFS 
for patients treated after 1997 was 72.3% compared to 
56.5% for those treated before 1997 (P=.4; log rank 
test). Eight of the 12 patients who received CMT were 
treated after 1997, and almost all were treated using an 
ABVD-containing regimen. 
Factors in these high-risk patients that may con-
tribute to outcome and help in prognostication include 
age, gender, number of lymph nodal sites involved, 
sites of extranodal involvement and response to ther-
apy. Predictably, by both univariate and multivariate 
analysis, achievement of complete response at the end 
of scheduled chemotherapy had a significant impact 
on survival (Table 4). The only extranodal site that 
predicted survival by univariate analysis was the lung. 
However, when this was included in the multivariate 
model, lung involvement lost its importance achieving 
only marginal significance. 
DISCUSSION
Modern treatment strategies have resulted in significant 
improvements in outcome for patients with HL. Most 
patients nowadays can expect a greater than 90% chance 
of treatment success. However, this high survival rate is 
primarily restricted to patients without disseminated 
disease; patients with dissemination (stage IV) in most 
pediatric and adult studies continue to suffer a worse 
outcome than all other stages, with disease-free survival 
rates ranging between 50% and 85%.2, 5,14,15 Our results 
confirm this difference in outcome. 
Treatment strategies for these patients have focused 
primarily on chemoreduction. However, use of radia-
tion therapy remains controversial. While some study 
groups have elected to restrict radiation therapy to only 
those patients with initial bulky disease or with residual 
disease following chemotherapy, others are continuing 
to use this modality for all patients, albeit with response-
directed restrictions on field and dose.2,4-5,14,16 The ma-
jority of our patients were treated with chemotherapy 
alone. Some patients received radiation therapy at the 
discretion of the treating physician; these were patients 
with either suboptimal responses to chemotherapy or 
with initial bulky sites of disease. Our results suggest 
that there does seem to be some benefit of additional 
therapy for patients who suffered a suboptimal response 
to chemotherapy. On the other hand, radiation as con-
solidation for patients who had achieved a complete re-
sponse to chemotherapy did not result in an additional 
positive impact on the outcome. This result is consis-
tent with Loeffler et al, who questioned the benefit of 
adding radiation therapy after a meta-analysis of stud-
ies that randomized patients to receive chemotherapy 
alone or CMT.17 Other investigators have concurred, 
suggesting no benefit of additional radiation therapy.18 
However, considerable confusion remains regarding the 
Table 2.  Chemotherapy in patients with stage IV disease. 
Regimen n
ABVD 12
mOPP 25
COPP 1
Combination 17
   mOPP/ABVD 3
   COPP/ABVD 9
   Other 5
Total 55
ABVD: Adriamycin, bleomycin, vinblastine, dacarbazine, mOPP: mechlorethamine, 
vincristine, procarbazine, prednisone, COPP: cyclophosphamide, vincristine, 
procarbazine, prednisone.
Table 3. Combined modality therapy in patients with Stage IV 
disease.
Chemotherapy n Radiotherapy n
ABVD 5
1500 cGy IF 1
1500 cGy EF 2
3500 cGy IF 1
3600 cGy IF 1
ABVD/COPP 6
1500 cGy IF 2
1500 cGy EF 3
4140 cGy IF 1
3000 cGy IF 1
mOPP 1 3000 cGy IF 1
IF= involved field; EF= extended field. ABVD: Adriamycin, bleomycin, vinblastine, 
dacarbazine, mOPP: mechlorethamine, vincristine, procarbazine, prednisone, COPP: 
cyclophosphamide, vincristine, procarbazine, prednisone.
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Figure 1. Percentage distribution of histological subtypes comparing stage IV with 
all other stages. LP=lymphocyte predominance; NS=nodular sclerosis; mC=mixed 
cellularity; LD=lymphocyte depletion.
utility of radiation therapy. Nachman et al showed a 
statistically significant benefit for radiation therapy in 
a clinical trial that randomized patients who achieved 
complete response to chemotherapy to receive radiation 
therapy or not.8 More recently, in an update of the same 
protocol, it was suggested that the benefit for radiation 
therapy may be restricted only to subsets of patients 
definable by histology and clinical risk features.19 This 
would suggest that attempts at improvement in the out-
come for these patients should rely on identification of 
these higher risk patients, either by pre-treatment risk 
stratification or by response evaluation. Addition of ra-
diation therapy to existing chemotherapy protocols or 
increasing the efficacy of chemotherapy could then be 
utilized for those patients who are likely not to achieve 
an optimal response.
Prognostication and risk scoring has been used for 
several malignancies to determine appropriate thera-
peutic intensity. The International Prognostic Score for 
HL has significant utility in this regard, but is definitely 
more relevant in adult patients.20 Several other prog-
nostic scores that have been developed, in particular for 
advanced stage HL, have not included children (≤14 
years) either in their initial evaluation or during subse-
quent validation.21,22 Smith et al reported the results of 
a multi-institutional clinical trial in pediatric patients 
with HL and proposed a prognostic scoring system.14 
This included five criteria (male gender, high stage, bulky 
mediastinal disease, WBC >13.5×109/L and hemoglo-
bin <11 g/L) that were found to independently predict 
inferior outcome. Application of this scoring system on 
our cohort of stage IV patients did not further catego-
rize patients according to outcome (patients with scores 
of 1-3 v. 4-5; OS 79.7% v. 78.8%; EFS 60.6% v. 64.2%; 
P>.5 [log rank test] for both comparisons). One other 
study of prognostic factors in pediatric HL patients 
found only stage IV as an independent risk factor on 
multivariate analysis.23 Our own efforts to identify prog-
nostic variables that might predict outcome and guide 
treating physicians in clinical decision making failed to 
reveal any pre-treatment variables of significance.
As expected, response to treatment in these very 
high-risk patients did predict eventual outcome. 
Although the methodology used to determine response 
to therapy in our study was fairly crude when compared 
to current available techniques, clearly a complete re-
sponse to chemotherapy does predict a superior out-
come. The availability of functional imaging such as 
FDG-positron emission tomography (FDG-PET) has 
resulted in more sensitive assessments of therapeutic re-
sponse. FDG-PET has a significant predictive value in 
patients with advanced stage disease and can potentially 
Table 4. Effect of predictor variables on survival (logistic regression analysis).
Risk factors Exp (B) 95% confidence interval of Exp (B) P
Unadjusted analysis
Age at diagnosis 1.002 0.822-1.222 .983  .908a
Gender (male) 2.308 0.675-7.892 .183
No. of lymph node sites 
(1 vs. >1 lymph nodes) 0.255 0.015-4.354 .345
No. of lymph node sites 
(≤median vs. >median)b 0.953 0.278-3.272 .939
Lung involvement 5.750 1.479-22.358 .012
Liver involvement 0.293 0.081-1.059 .061
Bone and/or bone marrow 
involvement 1.543 0.455-5.234 .487
Failure to achieve complete 
response at end-of-
chemotherapy
37.5 7.228-94.544 <.001
Adjusted analysisc
Failure to achieve complete 
response at end-of-
chemotherapy
73.595 7.336-738.309 <.001
Lung involvement 9.378 0.866-101.612 .066
amann-Whitney U-Test; bmedian number of lymph node sites = 4; cAdjusted for age at diagnosis, gender, lymph nodes 
sites (≤ median vs. > median), lung, liver, bone and/or bone marrow involvement and failure to achieve Cr-1. relapse/
PD was not included in the model due to its highly significant dependence on failure to achieve Cr-1 (P<.0001, Fisher 
exact test). 
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has remained effective therapy for most patients, clini-
cal trial results using BEACOPP (bleomycin, eto-
poside, Adriamycin, cyclophosphamide, vincristine, 
procarbazine, prednisone and escalated BEACOPP 
have shown significant advantages, particularly in the 
advanced stage patients.4,10,16 Such intensive protocols 
may result in a lower incidence of poor early response 
to chemotherapy, more complete responses at the end of 
scheduled chemotherapy and possibly a better disease 
outcome. However, there is the potential for significant 
toxicity in pediatric patients,27 maybe at the cost of 
be used to tailor therapeutic strategies.24-26 For stage IV 
patients, where risk of treatment failure is significantly 
higher than for other stages, a suboptimal response to 
two or three cycles of standard therapy could be an 
indication for using more intensive or novel therapy, 
which may include autologous stem cell transplantation 
or targeted immunotherapy. However, more study is re-
quired before this suggestion could be implemented as 
a recommendation.
Intensification of first-line therapy to improve initial 
responses may also be a feasible strategy. While ABVD 
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Figure 2. Overall and event-free survival for patients with stage IV (blue line) and stages I-III (red line).  5-year overall survival for 
stage IV is 79.4% and for stages I-III is 97.5% (P<.001; Log-rank test).  5-year EFS for stage IV is 63.9% and for stages I-III is 83.8% 
(P<.001; Log-rank test).
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Figure 3. Overall and event-free survival for patients treated with chemotherapy (CTX) alone (red line) and combined-modality therapy 
(CmT) (blue line).  5-year overall survival for CTX is 77.1% and for CmT is 91.7% (P=.3; log-rank test).  5-year EFS for CTX is 62.7% and 
for CmT is 70.7% (P=.4; Log-rank test).
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overtreatment for a subset of patients who may have re-
sponded well to less intensive regimens. This is certainly 
demonstrated in our cohort of patients who achieved a 
complete tumor response with less intensive protocols 
and had excellent outcomes.
In conclusion, HL patients with disease dissemina-
tion at diagnosis continue to pose a significant thera-
peutic dilemma. Attempts at risk stratification have as 
yet failed to yield any notable pre-treatment criteria. 
While treatment intensification has improved out-
comes for these patients, this may result in overtreat-
ment in a subset with the consequent risk of treat-
ment-related toxicity. Better criteria for measurement 
of treatment response as a mechanism for risk strati-
fication, and the identification of intensive or novel 
strategies for those patients with poor responses may 
be the best way to proceed with treatment in tradi-
tionally poor-risk HL patients.
1. Hudson mm.  Pediatric Hodgkin’s therapy: 
Time for a paradigm shift.  J Clin Oncol.  2002 
20(18); 3765-71.
2. Hudson mm, Krasin m, Link mP, Donaldson SS, 
Billups C, merchant TE, Kun L, Billet AL, Kaste S, 
Tarbell NJ, et al.  risk-adapted, combined-modal-
ity therapy with VAmP/COP and response-based, 
involved-field radiation for unfavorable pediatric 
Hodgkin’s disease.  J Clin Oncol.  2004 22(22); 4541-
50.
3. Kelly Km, Hutchinson rJ, Sposto r, Weiner 
mA, Lones mA, Perkins SL, massey V, Cohen r. 
Feasibility of upfront dose-intensive chemother-
apy in children with advanced-stage Hodgkin’s 
lymphoma: preliminary resultsform the Children’s 
Cancer Group study CCG-59704.  Ann Oncol.  2002 
13(S1): 107-11.
4. Franklin J, Diehl V.  Current clinical trials for the 
treatment of advanced-stage Hodgkin’s disease: 
BEACOPP.  Ann Oncol.  2002 13(S1): 98-101.
5. Horning SJ, Hoppe rT, Breslin S, Bartlett NL, 
Brown BW, rosenberg SA.  Stanford V and ra-
diotherapy for locally extensive and advanced 
Hodgkin’s disease: mature results of a prospective 
clinical trial.  J Clin Oncol.  2002 20(3): 630-7.
6. Brice P, Colin P, Berger F, de Kerviler E, Divine 
m, Bouaffia F, Kerneis Y, Blanc m, Lepage E, Ferme 
C.  Advanced Hodgkin disease with large mediasti-
nal involvement can be treated with eight cycles of 
chemotherapy alone after a major response to six 
cycles of chemotherapy.  Cancer 2001 92(3): 453-9. 
7. Aleman BmP, raemaekers Jmm, Tirelli U, 
Bortolus r, van’t Veer m, Lybeert mLm, Keuning 
JJ, Carde P, Girinsky T, et al.  Involved-field radio-
therapy in advanced Hodgkin’s lymphoma.  N Engl 
J med 2003 348(24):2396-406.
8. Nachman JB, Sposto r, Herzog P, Gilchrist GS, 
Wolden SL, Thomson J, Kadin mE, Pattengale P, 
Davis PC, Hutchinson rJ, White K.  randomized 
comparison of low-dose involved-field radiothera-
py and no radiotherapy for children with Hodgkin’s 
disease who achieve a complete response to che-
motherapy.  J Clin Oncol 2002 20(18): 3765-71.
9. Nachman JB.  radiation therapy in pediatric 
Hodgkin disease- who needs it? Ann Oncol  2008 
19(S4): 108.
10. V. Diehl, J. Franklin, B. Pfistner, A. Engert.  Ten-
year results of a German Hodgkin Study Group 
randomized trial of standard and increased dose 
BEACOPP chemotherapy for advanced Hodg-
kin lymphoma (HD9).  J Clin Oncol 2007 25(18S): 
LBA8015. 
11. Stein H, Delsol G, Pileri S, Said J, mann r, 
Poppema S, Jaffe ES, Swerdlow SH, Hodgkin lym-
phoma. In: Jaffe ES, Harris NL, Stein H, Vardimann 
JW, editors. Pathology and Genetics - Tumours of 
Haematopoietic and lymphoid tissues. Lyons: IArC 
Press; 2001:237-53.
12. Lister TA, Growther D, Sutcliffe SB, Glatstein 
E, Canellos GP, Young rC. report of a committee 
convened to discuss the evaluation and staging 
of patients with Hodgkin’s disease. J Clin Oncol. 
1989;7:1630-6.
13. Chow LmL, Nathan PC, Hodgson DC, Jenkin D, 
Weitzman S, Grant rm, et al. Survival and late ef-
fects in children with Hodgkin’s lymphoma treated 
with mOPP/ABV and low-dose, extended-field ir-
radiation.  J Clin Oncol 2006; 24(36): 5735-41. 
14. Smith rS, Chen Q, Hudson mm, Link mP, Kun L, 
Weinstein H, Billett A, marcus KJ, Tarbell NJ, Don-
aldson SS.  Prognostic factors for children with 
Hodgkin’s disease treated with combined-modal-
ity therapy.  J Clin Oncol  2003 21(10): 2026-33.
15. Armata J, Balwierz W, moryl-Bujakowska 
A, Boguslawska-Jaworska J, Pisarek J, Sonta-
Jakimczyk D, Janik-moszant A, et al.  Childhood 
stage IV Hodgkin disease: Therapeutic results of 
the Polish Pediatric Leukemia/Lymphoma Study 
Group.  med Pediatr Oncol  1999 33:382-7.
16. Diehl V, Franklin J, Hasenclever D, Tesch H, 
Pfreundschuh m, Lathan B, Paulus U, Sieber m, 
rueffer J-U, Sextro m, et al.  BEACOPP, a new 
dose-escalated and accelerated regimen, is at 
least as effective as COPP/ABVD in patients with 
advanced-stage Hodgkin’s lymphoma: Interim 
report from a trial of the German Hodgkin’s Lym-
phoma Study Group.  J Clin Oncol 1998 16(12): 
3810-21.
17. Loeffler m, Brosteanu O, Hasenclever D, Sex-
tro m, Assouline D, Bartolucci AA, Cassileth PA, 
Crowther D, Dielh V, Fisher rI, et al.  meta-analysis 
of chemotherapy versus combined modality treat-
ment trials in Hodgkin’s disease.  International 
database on Hodgkin’s Disease Overview Study 
Group.  J Clin Oncol  1998 16(3): 818-29.
18. Weiner mA, Leventhal B, Brecher mL, mar-
cus rB, Cantor A, Gieser PW, Ternberg JL, Behm 
FG, Wharam mD and Chauvenet Ar. randomized 
study of intensive mOPP-ABVD with or without 
low-dose total-nodal radiation therapy in the 
treatment of stages IIB, IIIA2, IIIB and IV Hodgkin’s 
disease in pediatric patients: A Pediatric Oncology 
Group study. J Clin Oncol, 1997; 15(8): 2769-79.
19. JB, Nachman. radiation therapy in pediatric 
Hodgkin disease- who needs it?  Ann Oncol, 2008; 
19(Suppl 4): iv108.
20. Hansclever D, Diehl V.  A prognostic score for 
advanced Hodgkin’s disease.  New Engl J med 
1998 339(21): 1506-14.
21. Gobbi PG, Zinzani PL, Broglia C, Comelli m, 
magagnoli m, Federico m, merli F, Iannitto E, Tura 
S, Ascari E.  Comparison of prognostic models in 
patients with advanced Hodgkin disease: promis-
ing results from integration of the best three sys-
tems.  Cancer 2001 91: 1467-78.
22. Vassilakopoulos TP, Angelopoulou mK, Siakan-
taris mP, Kontopidou FN, Dimopoulou mN, Bar-
bounis A, Grigorakis V, Karkantaris C, Anargyrou 
K, et al.  Prognostic factors in advanced stage 
Hodgkin’s lymphoma: the significance of number 
of involved anatomic sites.  Eur J Haematol 2001 
67: 279-88.
23. Oguz A, Karadinez C, Okur FV, Citak EC, Pinarli 
FG, Bora H, Akyurek N.  Prognostic factors and 
treatment outcome in childhood Hodgkin disease. 
Pediatr Blood Cancer 2005 45:670-5.
24. Gallamini A, Hutchings m, rigacci L, Specht L, 
merli F, Hansen m, Patti C, Loft A, Di raimondo F, 
D’Amore D, Biggi A, et al.  Early interim 2-[18F] flu-
oro-2-deoxy-D-glucose positron emission tomog-
raphy is prognostically superior to International 
Prognostic Score in advanced stage Hodgkin’s 
lymphoma: a report from a joint Italian-Danish 
study.  J Clin Oncol  2007 25(24): 3746-52.
25. Hutchings m, Loft A, Hansen m, Pedersen Lm, 
Buhl T, Jurlander J, Buus S, Keiding S, D’Amore F, et 
al.  FDG-PET after two cycles of chemotherapy pre-
dicts treatment failure and progression-free survival 
in Hodgkin lymphoma.  Blood  2006 107(1): 52-9.
26. Hutchings m, mikhaeel NG, Fields PA, Nunan 
T, Timothy Ar.  Prognostic value of interim FDG-
PET after two or three cycles of chemotherapy in 
Hodgkin lymphoma.  Ann Oncol 2005 16: 1160-8.
27. Kelly Km, Hutchinson rJ, Sposto r, Weiner 
mA, Lones mA, Perkins SA, massey V and Cohen 
r. Feasibility and upfront dose-intensive chemo-
therapy in children with advanced-stage Hodgkin’s 
lymphoma: preliminary results from the Children’s 
Cancer Group study CCG 59704. Ann Oncol, 2002; 
13(Suppl 1): 107-11.
REFERENCES
